FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894903073> ?p ?o ?g. }

• W2894903073 endingPage "432" @default.
• W2894903073 startingPage "424" @default.
• W2894903073 abstract "ObjectivesThe aim was to compare the antimicrobial efficacy of four different grafts: a standard graft (Intergard, IG), an IG graft soaked in rifampicin (IGrif), a silver impregnated graft (Intergard Silver, IGS), and a silver + triclosan impregnated graft (Intergard Synergy, IGSy).MethodsThis was a seven day in vitro study. The IG, IGrif, IGS, and IGSy grafts were each contaminated separately with the following microorganisms: Staphylococcus epidermidis, Methicillin resistant Staphylococcus aureus (MRSA), Escherichia coli, and Candida albicans from both clinical and American Type Culture Collection (ATCC) origins. The in vitro antimicrobial efficacy was evaluated by time to kill assays at T0, T24h, T48h, T72h, and T168h. Bactericidal activity was defined as >3 log10 reduction factor (logRF). Additionally, Rifampicin, triclosan and silver resistance development were screened.ResultsAs anticipated for the non-antimicrobial IG, all microorganism strains proliferated. The IGSy and the IGS showed a seven day bactericidal efficacy (>3 logRF) for all tested microorganisms. This efficacy was confirmed at all time points for IGSy only, demonstrating faster bactericidal efficacy than IGS. The IGrif demonstrated a seven day bactericidal efficacy against the ATCC MRSA only, while showing no activity against C. albicans and ATCC E. coli. Regarding ATCC S. epidermidis, clinical MRSA and clinical E. coli, IGrif, although bactericidal at earlier time points, lost its antimicrobial efficacy at seven days leading to the emergence of rifampicin resistant mutants in four of six, two of six, and two of six assays, respectively. Mutant strains were also detected in ATCC MRSA in one of six assays. No triclosan or silver resistance has emerged at T7days.ConclusionFor all microorganisms tested, the Synergy graft combining silver with triclosan demonstrated a more sustainable and efficient seven day antimicrobial activity than the rifampicin soaked graft. The emergence of rifampicin resistant mutants suggests preference for a Synergy graft over a graft soaked in rifampicin, to prevent or treat an infection when a biological solution is not feasible. The aim was to compare the antimicrobial efficacy of four different grafts: a standard graft (Intergard, IG), an IG graft soaked in rifampicin (IGrif), a silver impregnated graft (Intergard Silver, IGS), and a silver + triclosan impregnated graft (Intergard Synergy, IGSy). This was a seven day in vitro study. The IG, IGrif, IGS, and IGSy grafts were each contaminated separately with the following microorganisms: Staphylococcus epidermidis, Methicillin resistant Staphylococcus aureus (MRSA), Escherichia coli, and Candida albicans from both clinical and American Type Culture Collection (ATCC) origins. The in vitro antimicrobial efficacy was evaluated by time to kill assays at T0, T24h, T48h, T72h, and T168h. Bactericidal activity was defined as >3 log10 reduction factor (logRF). Additionally, Rifampicin, triclosan and silver resistance development were screened. As anticipated for the non-antimicrobial IG, all microorganism strains proliferated. The IGSy and the IGS showed a seven day bactericidal efficacy (>3 logRF) for all tested microorganisms. This efficacy was confirmed at all time points for IGSy only, demonstrating faster bactericidal efficacy than IGS. The IGrif demonstrated a seven day bactericidal efficacy against the ATCC MRSA only, while showing no activity against C. albicans and ATCC E. coli. Regarding ATCC S. epidermidis, clinical MRSA and clinical E. coli, IGrif, although bactericidal at earlier time points, lost its antimicrobial efficacy at seven days leading to the emergence of rifampicin resistant mutants in four of six, two of six, and two of six assays, respectively. Mutant strains were also detected in ATCC MRSA in one of six assays. No triclosan or silver resistance has emerged at T7days. For all microorganisms tested, the Synergy graft combining silver with triclosan demonstrated a more sustainable and efficient seven day antimicrobial activity than the rifampicin soaked graft. The emergence of rifampicin resistant mutants suggests preference for a Synergy graft over a graft soaked in rifampicin, to prevent or treat an infection when a biological solution is not feasible." @default.
• W2894903073 created "2018-10-12" @default.
• W2894903073 creator A5034188081 @default.
• W2894903073 creator A5040250194 @default.
• W2894903073 creator A5045765177 @default.
• W2894903073 creator A5052384607 @default.
• W2894903073 creator A5056077016 @default.
• W2894903073 creator A5056964163 @default.
• W2894903073 creator A5070088377 @default.
• W2894903073 creator A5083149438 @default.
• W2894903073 date "2019-03-01" @default.
• W2894903073 modified "2023-10-16" @default.
• W2894903073 title "In vitro Evidence of Improved Antimicrobial Efficacy of Silver and Triclosan Containing Vascular Grafts Compared with Rifampicin Soaked Grafts" @default.
• W2894903073 cites W1543474898 @default.
• W2894903073 cites W1974722697 @default.
• W2894903073 cites W1987758882 @default.
• W2894903073 cites W2006690524 @default.
• W2894903073 cites W2016811804 @default.
• W2894903073 cites W2021345718 @default.
• W2894903073 cites W2027549610 @default.
• W2894903073 cites W2035407653 @default.
• W2894903073 cites W2042174800 @default.
• W2894903073 cites W2064842252 @default.
• W2894903073 cites W2070275568 @default.
• W2894903073 cites W2089077011 @default.
• W2894903073 cites W2090090755 @default.
• W2894903073 cites W2119490605 @default.
• W2894903073 cites W2124836962 @default.
• W2894903073 cites W2144706728 @default.
• W2894903073 cites W2146152428 @default.
• W2894903073 cites W2147516488 @default.
• W2894903073 cites W2152539173 @default.
• W2894903073 cites W2160297228 @default.
• W2894903073 cites W2164513795 @default.
• W2894903073 cites W2194098207 @default.
• W2894903073 cites W2529883298 @default.
• W2894903073 cites W2768721964 @default.
• W2894903073 cites W2778637909 @default.
• W2894903073 doi "https://doi.org/10.1016/j.ejvs.2018.08.053" @default.
• W2894903073 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30301647" @default.
• W2894903073 hasPublicationYear "2019" @default.
• W2894903073 type Work @default.
• W2894903073 sameAs 2894903073 @default.
• W2894903073 citedByCount "26" @default.
• W2894903073 countsByYear W28949030732019 @default.
• W2894903073 countsByYear W28949030732020 @default.
• W2894903073 countsByYear W28949030732021 @default.
• W2894903073 countsByYear W28949030732022 @default.
• W2894903073 countsByYear W28949030732023 @default.
• W2894903073 crossrefType "journal-article" @default.
• W2894903073 hasAuthorship W2894903073A5034188081 @default.
• W2894903073 hasAuthorship W2894903073A5040250194 @default.
• W2894903073 hasAuthorship W2894903073A5045765177 @default.
• W2894903073 hasAuthorship W2894903073A5052384607 @default.
• W2894903073 hasAuthorship W2894903073A5056077016 @default.
• W2894903073 hasAuthorship W2894903073A5056964163 @default.
• W2894903073 hasAuthorship W2894903073A5070088377 @default.
• W2894903073 hasAuthorship W2894903073A5083149438 @default.
• W2894903073 hasBestOaLocation W28949030731 @default.
• W2894903073 hasConcept C142724271 @default.
• W2894903073 hasConcept C2777949923 @default.
• W2894903073 hasConcept C2778607973 @default.
• W2894903073 hasConcept C2779489039 @default.
• W2894903073 hasConcept C2780917455 @default.
• W2894903073 hasConcept C2781289450 @default.
• W2894903073 hasConcept C4937899 @default.
• W2894903073 hasConcept C501593827 @default.
• W2894903073 hasConcept C523546767 @default.
• W2894903073 hasConcept C54355233 @default.
• W2894903073 hasConcept C71924100 @default.
• W2894903073 hasConcept C86803240 @default.
• W2894903073 hasConcept C89423630 @default.
• W2894903073 hasConceptScore W2894903073C142724271 @default.
• W2894903073 hasConceptScore W2894903073C2777949923 @default.
• W2894903073 hasConceptScore W2894903073C2778607973 @default.
• W2894903073 hasConceptScore W2894903073C2779489039 @default.
• W2894903073 hasConceptScore W2894903073C2780917455 @default.
• W2894903073 hasConceptScore W2894903073C2781289450 @default.
• W2894903073 hasConceptScore W2894903073C4937899 @default.
• W2894903073 hasConceptScore W2894903073C501593827 @default.
• W2894903073 hasConceptScore W2894903073C523546767 @default.
• W2894903073 hasConceptScore W2894903073C54355233 @default.
• W2894903073 hasConceptScore W2894903073C71924100 @default.
• W2894903073 hasConceptScore W2894903073C86803240 @default.
• W2894903073 hasConceptScore W2894903073C89423630 @default.
• W2894903073 hasIssue "3" @default.
• W2894903073 hasLocation W28949030731 @default.
• W2894903073 hasLocation W28949030732 @default.
• W2894903073 hasLocation W28949030733 @default.
• W2894903073 hasLocation W28949030734 @default.
• W2894903073 hasOpenAccess W2894903073 @default.
• W2894903073 hasPrimaryLocation W28949030731 @default.
• W2894903073 hasRelatedWork W1825759935 @default.
• W2894903073 hasRelatedWork W1926828953 @default.
• W2894903073 hasRelatedWork W1969303506 @default.
• W2894903073 hasRelatedWork W2087099839 @default.
• W2894903073 hasRelatedWork W2461081619 @default.
• W2894903073 hasRelatedWork W2463572106 @default.

• next